Product Pipeline

Morphotek has leveraged its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. Through a series of collaborations with leading research institutes and commercial partners, Morphotek has gained access to validated disease targets and is developing and investigating monoclonal antibodies and antibody drug conjugates for the treatment of target-positive diseases.

Morphotek applies its proprietary antibody optimization technology to yield antibodies that possess high-affinity and high-titer characteristics, as well as improved effector function and cytotoxic activity, and candidates that are suitable for pharmaceutical product development.

*Ongoing confirmatory Phase 2 study in recurrent platinum-sensitive epithelial ovarian cancer patients with a low CA125 level.